Profile data is unavailable for this security.
About the company
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. It has also obtained an early-stage program for atopic dermatitis, STAR0310.
- Revenue in USD (TTM)874.84m
- Net income in USD263.86m
- Incorporated1991
- Employees435.00
- LocationBioCryst Pharmaceuticals Inc4505 Emperor Blvd Ste 200DURHAM 27703-8457United StatesUSA
- Phone+1 (302) 636-5400
- Fax+1 (302) 636-5454
- Websitehttps://www.biocryst.com/
More ▼
Mergers & acquisitions
| Acquired company | BCRX:NSQ since announced | Transaction value |
|---|---|---|
| Astria Therapeutics Inc | 23.44% | 716.93m |
Data delayed at least 15 minutes, as of Mar 03 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nektar Therapeutics | 62.60m | -120.74m | 1.86bn | 61.00 | -- | 15.73 | -- | 29.69 | -7.93 | -7.93 | 4.10 | 4.33 | 0.2055 | -- | 97.13 | 1,026,230.00 | -37.21 | -35.30 | -47.69 | -39.56 | 87.26 | 75.63 | -181.08 | -323.39 | -- | -8.54 | 0.469 | -- | 9.22 | -3.00 | 56.91 | -- | -43.84 | -- |
| Recursion Pharmaceuticals Inc | 74.68m | -644.76m | 1.87bn | 600.00 | -- | 1.65 | -- | 25.00 | -1.48 | -1.48 | 0.167 | 2.14 | 0.0511 | -- | 2.02 | 124,468.30 | -44.12 | -43.31 | -49.84 | -49.18 | 4.99 | -- | -863.35 | -816.44 | -- | -- | 0.0162 | -- | 26.92 | 79.91 | -39.06 | -- | 2.10 | -- |
| Syndax Pharmaceuticals Inc | 172.60m | -285.42m | 1.89bn | 298.00 | -- | 28.94 | -- | 10.94 | -3.30 | -3.30 | 2.00 | 0.7394 | 0.2752 | 0.4209 | 7.57 | 579,191.30 | -45.50 | -34.74 | -55.38 | -38.78 | 95.96 | -- | -165.37 | -279.37 | 4.12 | -24.68 | 0.8418 | -- | 627.84 | 157.68 | 10.46 | -- | -- | -- |
| Celldex Therapeutics Inc | 1.55m | -258.76m | 1.93bn | 198.00 | -- | 3.65 | -- | 1,246.07 | -3.90 | -3.90 | 0.0233 | 7.92 | 0.0023 | -- | 1.14 | 7,808.08 | -37.63 | -30.06 | -40.28 | -31.85 | -- | -- | -16,737.19 | -3,299.27 | -- | -- | 0.00 | -- | -77.99 | -26.93 | -63.91 | -- | 11.83 | -- |
| Stoke Therapeutics Inc | 205.63m | 40.57m | 1.93bn | 128.00 | 51.18 | 6.04 | 45.44 | 9.38 | 0.66 | 0.66 | 3.52 | 5.59 | 0.6293 | -- | 35.68 | 1,606,500.00 | 12.41 | -34.04 | 14.44 | -37.36 | -- | -- | 19.73 | -749.56 | -- | -- | 0.00 | -- | 316.34 | -- | 15.01 | -- | -34.11 | -- |
| Soleno Therapeutics Inc | 190.41m | 20.48m | 1.95bn | 182.00 | 244.03 | 4.38 | 85.01 | 10.23 | 0.1546 | 0.1546 | 3.61 | 8.61 | 0.4256 | -- | -- | 1,046,181.00 | 4.67 | -28.03 | 5.13 | -30.82 | 98.58 | -- | 10.97 | -130.73 | 5.55 | -- | 0.0997 | -- | -- | -- | 111.64 | -- | 59.83 | -- |
| Maze Therapeutics Inc | 0.00 | -101.46m | 2.13bn | 125.00 | -- | 5.60 | -- | -- | -2.68 | -2.68 | 0.00 | 7.89 | 0.00 | -- | -- | 0.00 | -41.05 | -- | -43.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 103.39 | -- | -- | -- |
| Grail Inc | 147.17m | -408.35m | 2.13bn | 1.00k | -- | 0.8254 | -- | 14.46 | -11.18 | -11.18 | 4.01 | 63.92 | 0.0498 | -- | 7.62 | -- | -13.83 | -- | -14.21 | -- | 48.46 | -- | -277.47 | -- | -- | -- | -- | -- | 17.18 | -- | 79.85 | -- | -- | -- |
| BioCryst Pharmaceuticals Inc | 874.84m | 263.86m | 2.18bn | 435.00 | 7.22 | -- | 8.16 | 2.49 | 1.20 | 1.20 | 4.00 | -0.5593 | 1.74 | 2.83 | 9.41 | 2,011,120.00 | 52.53 | -18.78 | 81.42 | -25.41 | 97.82 | 97.60 | 30.16 | -23.15 | 2.03 | 4.99 | 1.34 | -- | 94.10 | 117.89 | 396.87 | -- | 36.86 | -- |
| Mineralys Therapeutics Inc | 0.00 | -171.36m | 2.26bn | 51.00 | -- | 3.91 | -- | -- | -2.96 | -2.96 | 0.00 | 7.30 | 0.00 | -- | -- | 0.00 | -39.48 | -- | -42.14 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -147.31 | -- | -- | -- |
| Dyne Therapeutics Inc | 0.00 | -446.21m | 2.36bn | 258.00 | -- | 2.48 | -- | -- | -3.54 | -3.54 | 0.00 | 5.89 | 0.00 | -- | -- | 0.00 | -47.52 | -55.84 | -49.99 | -60.48 | -- | -- | -- | -- | -- | -- | 0.1328 | -- | -- | -- | -40.58 | -- | 77.94 | -- |
| Dianthus Therapeutics Inc | 3.08m | -126.35m | 2.37bn | 78.00 | -- | 4.34 | -- | 771.57 | -3.48 | -3.48 | 0.085 | 12.75 | 0.0066 | -- | 0.8013 | 39,461.54 | -27.12 | -37.13 | -28.32 | -39.78 | -- | -- | -4,104.78 | -3,874.39 | -- | -- | 0.00 | -- | 120.63 | -- | -95.08 | -- | -49.06 | -- |
| Immunome Inc | 9.68m | -222.74m | 2.38bn | 118.00 | -- | 7.48 | -- | 245.54 | -2.95 | -2.95 | 0.122 | 2.88 | 0.0348 | -- | -- | 82,025.42 | -80.08 | -120.50 | -91.80 | -146.20 | -- | -- | -2,301.30 | -2,078.20 | -- | -- | 0.00 | -- | -35.50 | -- | -174.29 | -- | 196.63 | -- |
| Disc Medicine Inc | 0.00 | -212.18m | 2.46bn | 155.00 | -- | 3.30 | -- | -- | -5.98 | -5.98 | 0.00 | 19.53 | 0.00 | -- | -- | 0.00 | -32.55 | -30.94 | -34.12 | -32.93 | -- | -- | -- | -- | -- | -- | 0.0379 | -- | -- | -- | -94.03 | -- | -- | -- |
| Adaptive Biotechnologies Corp | 276.98m | -59.50m | 2.48bn | 624.00 | -- | 11.30 | -- | 8.94 | -0.3987 | -0.3987 | 1.79 | 1.42 | 0.5265 | 7.82 | 6.01 | 443,871.80 | -11.30 | -22.45 | -13.86 | -25.94 | 74.24 | 66.23 | -21.47 | -88.21 | 3.23 | -24.47 | 0.3684 | -- | 54.77 | 23.00 | 62.69 | -- | -30.92 | -- |
Data as of Mar 03 2026. Currency figures normalised to BioCryst Pharmaceuticals Inc's reporting currency: US Dollar USD
40.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 20.53m | 8.28% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 16.94m | 6.83% |
| RA Capital Management LPas of 31 Dec 2025 | 15.83m | 6.38% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 11.07m | 4.46% |
| Kynam Capital Management LPas of 31 Dec 2025 | 9.37m | 3.78% |
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 7.31m | 2.95% |
| UBS Securities LLCas of 31 Dec 2025 | 5.26m | 2.12% |
| Geode Capital Management LLCas of 31 Dec 2025 | 5.05m | 2.04% |
| Two Sigma Investments LPas of 31 Dec 2025 | 4.52m | 1.82% |
| Two Sigma Advisers LPas of 31 Dec 2025 | 4.09m | 1.65% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
